S1257
Clinical - Urology
ESTRO 2026
Jyväskylä, Finland. 3 Faculty of medicine, University of Eastern Finland, Kuopio, Finland
Digital Poster 3309
Feasibility of quantitative HyperSight™ CBCT-based muscle monitoring during prostate radiotherapy Victor Siefert 1,2 , Joana Bettenhausen 1 , Alicia S. Bicu 1,2 , Ralf Schmidt 1,2 , Marvin Wilam 1 , Miriam Eckl 1 , Florian Stieler 1,3 , Michael Ehmann 1,2 , Daniel Bürgy 1,2 , Jens Fleckenstein 1 , Matthias F. Froelich 4 , Stefan O. Schoenberg 4 , Frank A. Giordano 1,2 , Judit Boda- Heggemann 1,2 , Constantin Dreher 1,2 1 Department of Radiation Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, Mannheim, Germany. 2 DKFZ-Hector Cancer Institute, University Medical Centre Mannheim, Mannheim, Germany. 3 Junior Research Group “Image and Surface guided Radiotherapy”, Mannheim Institute for Intelligent Systems in Medicine (MIiSM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 4 Department of Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim, Mannheim, Germany Purpose/Objective: Sarcopenia and treatment-induced muscle loss may be associated with increased toxicity during radiotherapy (RT). Daily HyperSight™ cone-beam computed tomography (CBCT) enables repeated soft- tissue imaging with quantitative Hounsfield units (HU), allowing dynamic monitoring of muscle composition [1]. This study evaluated the feasibility and clinical relevance of CBCT-derived muscle assessment during prostate RT. Material/Methods: Forty-one men undergoing definitive normo- or moderately hypofractionated prostate RT (Ethos®, Varian, Siemens Healthineers) were prospectively analyzed. Muscle segmentation as a sarcopenia surrogate was performed on the planning CT (BigBore,
Conclusion: These findings support AHRT as a comparable alternative to EHRT in the management of low- to intermediate-risk, localized PCa. Increased adoption of AHRT can improve access to care, patient convenience, and cost effectiveness. References: 1. Kishan AU, Sun Y, et al. Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium. Lancet Oncol. Apr 2025;26(4):459-469.2. Widmark A, Gunnlaugsson A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non- inferiority, phase 3 trial. Lancet. Aug 3 2019;394(10196):385-395. 3. Brand DH, Tree AC, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. Nov 2019;20(11):1531-1543. Keywords: Prostate cancer, Hypofractionation, Stereotactic
Digital Poster Highlight 3282
Stereotactic body radiotherapy for localized prostate cancer – 10-year follow-up results Kristiina Vuolukka 1,2 , Iida Salonen 3 , Sami Perälä 3 , Päivi Auvinen 1 , Janne Heikkilä 1 , Jan Seppälä 1 1 Cancer Center, Kuopio University Hospital, Kuopio, Finland. 2 Department of Radiotherapy and Oncology, Wellbeing Services County of Central Finland,
Made with FlippingBook - Share PDF online